Tularik
San Francisco
About Tularik
Tularik engages in the discovery and development of orally available medicines that act through the regulation of gene expression. The company is considered a pioneer in the field of cell signaling and the control of gene expression. The company is focused primarily of three main areas; inflammation, metabolic diseases and oncology. Tularik was founded by David Goeddel along with Steve McKnight and Robert Tjian in 1991. The company was acquired by Amgen for US$ 1.3 billion in 2004.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Funding stage: M&A
- Last round: Undisclosed (Jan 1991)
- Ticker: nasdaq:TLRK
- Website: tularik.com
Industries & Categories
Biopharma, Biotechnology, Genetics, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/tularik-2100831 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.